The Best Offense?

The Best Offense? CCR5 inhibitors, moving toward market, suggest it may be a good defense By Simon Frantz Related Articles 5 HIV Treatment Strategies A piggyback attack: Using the common cold to deliver an HIV vaccine Stem cells and gene therapy: Researchers take a second look at using stem cells to treat HIV Solving the viral spike: Can structural biology find a chink in HIV's armor? Reconstructing early HIV: The search for immunogen

Written bySimon Frantz

| 3 min read

Listen with Speechify

0:00

3:00

By Simon Frantz

5 HIV Treatment Strategies

A piggyback attack: Using the common cold to deliver an HIV vaccine

Stem cells and gene therapy: Researchers take a second look at using stem cells to treat HIV

Solving the viral spike: Can structural biology find a chink in HIV's armor?

Reconstructing early HIV: The search for immunogens delves into the virus' past

Profile: A Receptive Leader: Panacos' Graham Allaway

PODCAST: Andrea Gawrylewski interviews NIAID director Anthony Fauci, who gives his take on HIV research priorities.

All oral HIV drugs work by fighting the virus once it has entered human immune cells. Soon, however, defense could be a new form of attack. A CCR5 inhibitor called maraviroc is close to being the first oral treatment for HIV patients that prevents the virus entering uninfected host cells.

In the early 1990s the concept of creating HIV drugs that target host immune cells began ...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!

Join for free today

Already a member? Login Here